scholarly journals Intraventricular Enzyme Replacement Improves Disease Phenotypes in a Mouse Model of Late Infantile Neuronal Ceroid Lipofuscinosis

2008 ◽  
Vol 16 (4) ◽  
pp. 649-656 ◽  
Author(s):  
Michael Chang ◽  
Jonathan D Cooper ◽  
David E Sleat ◽  
Seng H Cheng ◽  
James C Dodge ◽  
...  
Keyword(s):  
Mouse Model ◽  
Neuronal Ceroid Lipofuscinosis ◽  
Infantile Neuronal Ceroid Lipofuscinosis ◽  
Enzyme Replacement ◽  
Disease Phenotypes ◽  
Ceroid Lipofuscinosis

scholarly journals The blood-brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol

2012 ◽  
Vol 21 (10) ◽  
pp. 2233-2244 ◽  
Author(s):  
Arjun Saha ◽  
Chinmoy Sarkar ◽  
Satya P. Singh ◽  
Zhongjian Zhang ◽  
Jeeva Munasinghe ◽  
...  
Keyword(s):  
Mouse Model ◽  
Blood Brain Barrier ◽  
Neuronal Ceroid Lipofuscinosis ◽  
Brain Barrier ◽  
Infantile Neuronal Ceroid Lipofuscinosis ◽  
Ceroid Lipofuscinosis ◽  
Blood Brain

Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2

2019 ◽  
Vol 35 (5) ◽  
pp. 348-353 ◽  
Author(s):  
Grace Lewis ◽  
Amanda M. Morrill ◽  
Stephanie L. Conway-Allen ◽  
Bernard Kim
Keyword(s):  
Adverse Events ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Neuronal Ceroid Lipofuscinosis ◽  
Efficacy And Safety ◽  
Infantile Neuronal Ceroid Lipofuscinosis ◽  
Enzyme Replacement ◽  
Ceroid Lipofuscinosis ◽  
Tract Infections

The objective of this review is to summarize the pharmacology, efficacy, and safety of cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2). Cerliponase alfa is recombinant human tripeptidyl peptidase 1 enzyme replacement therapy. A phase 1/2 trial established the efficacy and safety of cerliponase alfa for treatment of neuronal ceroid lipofuscinosis type 2. Treatment with intracerebroventricular cerliponase alfa resulted in slower decline of motor and language functions compared with natural history controls. Common adverse events include convulsions, electrocardiography abnormalities, pyrexia, vomiting, and upper respiratory tract infections. Intracerebroventricular device–related adverse events also occur. Cerliponase alfa is the first therapy for neuronal ceroid lipofuscinosis type 2 that targets the disease etiology. Cerliponase alfa is effective in delaying the progression of motor language decline for patients with neuronal ceroid lipofuscinosis type 2.

Sign in / Sign up

Export Citation Format

Share Document